Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis
Status:
Completed
Trial end date:
2017-08-16
Target enrollment:
Participant gender:
Summary
This is a single dose, open label study in adult male subjects with cystic fibrosis to
investigate the pharmacokinetics, safety and tolerability of GLPG2737.